reviewJournal of Experimental & Clinical Cancer ResearchApr 15, 2022GOLD OA

Emerging therapies for glioblastoma: current state and future directions

LRLiang RongNLNi LiZZZhenzhen Zhang

Sun Yat-sen University · South China Normal University

PubMed
Indexed incrossrefdoajpubmed

Abstract

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an extremely poor prognosis. Given the poor survival with currently approved treatments for GBM, new therapeutic strategies are urgently needed. Advances in decades of investment in basic science of glioblastoma are rapidly translated into innovative clinical trials, utilizing improved genetic and epigenetic profiling of glioblastoma as well as the brain microenvironment and immune system interactions. Following these encouraging findings, immunotherapy including immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy have offered new hope for improving GBM…

Citation impact

505
total citations
FWCI
49.30
Percentile
100%
References
191
Citations per year

Authors

3

Topics & keywords

Topics
Keywords
  • Medicine
  • Clinical trial
  • Chimeric antigen receptor
  • Oncolytic virus
  • Immunotherapy
  • Glioblastoma
  • Immune system
  • Immune checkpoint
No related works found for this paper.

Funding